ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) for AMGEN
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 20, 2021 | $60,000 | Replaced |
| 4th Quarter - Amendment (this page) | Jan 20, 2021 | $60,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to biosimilars, generally Issues related to drug pricing, value, and transparency, generally Issues related to the importation of prescription medicines Issues relating to the 340B Drug Pricing Program Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Taxation/Internal Revenue Code TAX
Tax issues related to Puerto Rico
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
Medicare/Medicaid MMM
Medicare Part B coverage and reimbursement issues Issues related to Medicare Part D Coding and reimbursement for oncology drugs/biologics/biosimilars
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.